EXTH-52. HARNESSING A B CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE

Abstract Glioblastoma (GBM) continues to retain its dismal prognosis despite numerous new therapeutic modalities target various aspects of the tumor. There is a need identify new, and even personalized, targetable GBM specific antigens. Our B-cell-based vaccine (BVax) generated by isolating immune experienced B cells, identified 4-1BBL, from murine secondary lymphoid organs or patient blood. We have shown this subset cells anti-tumoral potential in GBM. These are strengthened with BAFF, CD40, IFNg stimulation form BVax then activated vitro plasmablasts. Immunoprecipitation-mass spectrometry performed using BVax-derived antibodies tumor lysate paired specimen. unique antigens bound antibodies. Given significant benefit we seen preclinical models, hypothesize that targeting these would patients. focused on showed survival lower expression CGGA database analysis. confirm presence prevalence within patient’s tissue immunohistochemistry, identifying some up 15% cells. Using our brain bank repository, screened other for markers determine broader applicability each antigen. proteins key extracellular matrix formation which promote growth progression cancer, including ability induce epithelial-mesenchymal transition. Simultaneously developed computational algorithm predict will bind single cell RNA sequencing data patient-derived BVax, may larger number Both techniques serve as exciting platforms targets